Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.48 |
| ▸ | NPY1R | P25929 | 9/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.48 |
| ▸ | NPY2R | P49146 | 5/20 | 0.48 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18760235 | 1.00 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL18760211 | 1.00 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL16690636 | 1.00 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL18760234 | 1.00 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL16439025 | 0.90 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| Etelcalcetide SCHEMBL21982605 | 0.87 | SIRT5 (0.44) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| Etelcalcetide SCHEMBL20869502 | 0.87 | SIRT5 (0.44) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| Etelcalcetide SCHEMBL20869503 | 0.87 | SIRT5 (0.44) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| Etelcalcetide SCHEMBL22578458 | 0.86 | SIRT5 (0.43) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| Etelcalcetide SCHEMBL22578464 | 0.86 | SIRT5 (0.43) | NPY4RNPY1RNPY5RNPY2RSIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150126457-A1 | NEUROPROTECTIVE COMPOSITION AND METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126457-A1 | NEUROPROTECTIVE COMPOSITION AND METHOD OF USE | NLN, GAP43, BDNF | NPY4R 2092/4885NPY1R 1716/4885NPY5R 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.